Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
Nuo Therapeutics Inc. Stock Analysis AURX
United States N/A Micro Cap Nuo Therapeutics, Inc. engages in the development and sale of biomedical products for chronic wound care. The company is headquartered in Houston, Texas. The company went IPO on 2017-01-19. The firm is focused on developing and marketing products for chronic wound care primarily within the United States. The company has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The firm's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.
Read More Nuo Therapeutics Inc (AURX) Chart
Key Statistics of Nuo Therapeutics Inc (AURX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.90Volume
14.52KP/E Ratio (TTM)
-52 Week Range
Market Cap
48.89MAvg. Volume
3073.50Dividend Yield
-Financial Metrics & Statements of Nuo Therapeutics Inc (AURX)
FAQ's for Nuo Therapeutics Inc (AURX)
- According to Musaffa’s Shariah screening methodology, Nuo Therapeutics Inc (AURX) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nuo Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Nuo Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Nuo Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Nuo Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Nuo Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.